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Summary
Background The surgical burden of disease is substantial, but little is known about the associated economic 
consequences. We estimate the global macroeconomic impact of the surgical burden of disease due to injury, 
neoplasm, digestive diseases, and maternal and neonatal disorders from two distinct economic perspectives.
Methods We obtained mortality rate estimates for each disease for the years 2000 and 2010 from the Institute of Health 
Metrics and Evaluation Global Burden of Disease 2010 study, and estimates of the proportion of the burden of the selected 
diseases that is surgical from a paper by Shrime and colleagues. We ﬁ rst used the value of lost output (VLO) approach, 
based on the WHO’s Projecting the Economic Cost of Ill-Health (EPIC) model, to project annual market economy losses 
due to these surgical diseases during 2015–30. EPIC attempts to model how disease aﬀ ects a country’s projected labour 
force and capital stock, which in turn are related to losses in economic output, or gross domestic product (GDP). We then 
used the value of lost welfare (VLW) approach, which is conceptually based on the value of a statistical life and is inclusive 
of non-market losses, to estimate the present value of long-run welfare losses resulting from mortality and short-run 
welfare losses resulting from morbidity incurred during 2010. Sensitivity analyses were performed for both approaches.
Findings During 2015–30, the VLO approach projected that surgical conditions would result in losses of 1·25% of 
potential GDP, or $20·7 trillion (2010 US$, purchasing power parity) in the 128 countries with data available. When 
expressed as a proportion of potential GDP, annual GDP losses were greatest in low-income and middle-income 
countries, with up to a 2·5% loss in output by 2030. When total welfare losses are assessed (VLW), the present value of 
economic losses is estimated to be equivalent to 17% of 2010 GDP, or $14·5 trillion in the 175 countries assessed with 
this approach. Neoplasm and injury account for greater than 95% of total economic losses with each approach, but 
maternal, digestive, and neonatal disorders, which represent only 4% of losses in high-income countries with the VLW 
approach, contribute to 26% of losses in low-income countries.
Interpretation The macroeconomic impact of surgical disease is substantial and inequitably distributed. When paired 
with the growing number of favourable cost-eﬀ ectiveness analyses of surgical interventions in low-income and 
middle-income countries, our results suggest that building surgical capacity should be a global health priority.
Funding US National Institutes of Health/National Cancer Institute.
Copyright © Alkire et al. Open Access article distributed under the terms of CC BY.
Introduction
The global burden of surgical disease has only recently 
been deﬁ ned and subsequently estimated. Whereas ori-
ginal estimates suggested that up to 11% of global 
morbidity and mortality is secondary to surgical disease,1 
more recent eﬀ orts have suggested that that number is a 
vast underestimate and that up to 33% of the global 
burden of disease is surgical.2
Although an understanding of surgical morbidity and 
mortality is of paramount concern to researchers and policy 
makers alike, the downstream consequences of this burden 
are also of importance. One way to contextualise the impact 
of disease is to estimate the economic consequences it 
imposes. Although there is continued debate in the 
economic literature regarding how health and income are 
connected,3 there is strong evidence that improved popu-
lation health contributes positively to aggregate economic 
growth.4–10 Broadly speaking, the eﬀ ect of poor health can 
be examined at the microeconomic level, in which 
individuals, households, ﬁ rms, or other speciﬁ ed economic 
agents are studied, or at the macroeconomic level, in which 
the broader eﬀ ects on society as a whole are assessed.11
Some studies have investigated the economic impact of 
speciﬁ c surgical diseases at regional and global levels,12–14 
but little is known about the global economic impact of a 
more comprehensive set of surgical conditions. Using 
two distinct macroeconomic approaches, we sought to 
estimate: (1) the eﬀ ect of surgical disease mortality on 
annual global economic output during 2015–30, and 
(2) the eﬀ ect of surgical disease during a single year, 2010, 
on a more broadly deﬁ ned measure of economic welfare 
which incorporates a combination of long-run eﬀ ects of 
mortality and short-run eﬀ ects of morbidity.
Methods
Surgical burden of disease for selected conditions
We examined ﬁ ve major surgical disease categories: 
neoplasm, injury, maternal disorders, neonatal disorders, 
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and digestive disorders. We assumed that only a portion of 
the burden of each disease category is surgical. To this end, 
we used results from a survey instrument by Shrime and 
colleagues,2 which asked respondents, “What proportion 
of patients with the following conditions would, in an ideal 
world, require a surgeon for management?” for each of the 
21 categories in the Institute for Health Metrics and 
Evaluation’s (IHME) Global Burden of Disease.15,16
We selected the disease groups listed above because 
they have been repeatedly acknowledged to contribute to 
a large burden of surgical disease;1,17 under Shrime’s 
survey instrument, they contribute to more than 85% of 
all surgical deaths.2 Table 1 provides the mean responses 
from the survey; the speciﬁ c diseases contained within 
each IHME category are listed in the appendix.18 Table 1 
also gives an estimate of the global burden of the surgical 
proportions of the included conditions for 2010 using 
IHME estimates.15,16 The survey instrument and the 
deﬁ nition of surgical disease are discussed further in the 
appendix.
Macroeconomic approaches
This study uses two approaches to describe the macro-
economic consequences of surgical disease. These 
approaches were chosen because both allow for global 
economic modelling in the face of limited data, and each 
provides diﬀ erent information. The ﬁ rst approach is 
based on a model supplied by the WHO known as EPIC 
(Projecting the Economic Cost of Ill-health). We use the 
EPIC model to project annual market economy losses 
due to surgical disease during 2015–30, and, to be 
consistent with others who have used it,19 we term this 
approach the value of lost output (VLO). The second 
approach estimates the value of lost economic welfare 
(VLW) resulting from surgical disease in 2010. The 
counterfactual in both approaches is absence of disease. 
Estimates from both approaches are gross estimates, 
since they are not net of the cost of treatment.
The two approaches diﬀ er in two important ways: the 
deﬁ nition of economic loss, and the time period over 
which the loss is calculated. The VLO approach relates 
disease mortality to the labour supply and capital 
accumulation of a country over time. Changes in these 
factors result in decreased output of marketed goods and 
services, as measured in forgone gross domestic product 
(GDP). The EPIC model does not incorporate disease 
morbidity, which also aﬀ ects GDP. In this study, the VLO 
approach estimates the eﬀ ects of mortality on output in a 
given year during 2015–30. It is therefore a short-run 
measure, although the annual estimates can be summed 
to calculate cumulative eﬀ ects.
The VLW approach, also termed the full-income 
approach,20 relies on a concept known as the value of a 
statistical life, which incorporates non-market losses such 
as forgone leisure, non-health consumption, and the value 
of good health in and of itself. Consistent with previous 
studies of a similar scope to this one,19,21,22 we use the value 
of a statistical life approach to value disability-adjusted life 
years (DALYs), which capture both mortality and morbidity 
due to a disease in one metric. Owing to the manner in 
which DALYs are calculated,16 the VLW approach estimates 
the long-run eﬀ ects of life-years lost secondary to mortality, 
which is measured from an incidence perspective. 
Mortality estimates therefore include the eﬀ ects in 2010 
plus the present value of future eﬀ ects. Morbidity, 
however, is measured from a prevalence perspective, and 
therefore DALYs only capture the eﬀ ects of poor health in 
2010. Although a case of non-fatal surgical disease that 
occurred in 2010 could have persistent health eﬀ ects, 
future morbidity eﬀ ects of incident cases in 2010 are not 
what the current global burden of disease approach 
measures; rather, the prevalence of the disease of interest 
is estimated for 2010, and consequently this approach 
includes morbidity from diseases that were diagnosed 
before 2010.18 Since the VLW estimates include non-
market welfare losses due to mortality and morbidity, and, 
in the context of mortality represent long-run losses, they 
can be expected to be many times larger than the VLO 
estimates, which account only for market losses due to 
mortality (not morbidity) in the short term.
Results are presented in 2010 US$ and adjusted for 
purchasing power parity.23 The purchasing power parity 
method compares the price levels of a ﬁ xed basket of 
goods between countries to establish a currency 
conversion rate, such that the price of the basket of goods 
is the same in both countries when stated in the reference 
currency, usually US$. For each approach, countries 
were evaluated by IHME region and their respective 2010 
World Bank income classiﬁ cation.18,23
The appendix provides the mathematical details, 
assumptions, and data sources for each approach.
Sensitivity analyses
For each approach, we accounted for uncertainty in the 
estimation of the burden of disease by using the 
uncertainty intervals given by the IHME18 in addition to a 
lower and upper bound estimate of the proportion of 
Proportion 
of patients
Deaths 
(thousands)
YLLs 
(thousands)
YLDs 
(thousands)
Digestive 
disorders
30·3% 337 8246 1658
Injury 60·8% 3085 141 283 30 144
Maternal 
disorders
36·7% 93 5251 657
Neonatal 
disorders
27·3% 611 52 594 2586
Neoplasm 62·0% 4943 113 995 2777
Data are mean estimates from Shrime et al.2 DALY=disability-adjusted life year. 
YLL=non-discounted years of life lost (mortality) using Institute for Health Metrics and 
Evaluation standardised life-expectancy.15,16 YLD=years lost to disability (morbidity).
Table 1: Proportion of patients requiring a surgeon for management 
and implied burden of disease in 2010
See Online for appendix
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disease considered to be surgical, which we derive from 
95% CIs from Shrime and colleagues’ survey.2 This 
analysis was done as a two-way sensitivity analysis in 
which the models were run with the upper and lower 
bounds from Shrime and colleagues and IHME. 
Although probabilistic sensitivity analysis would have 
been preferred, the lack of information regarding the 
distribution and meaning of IHME uncertainty intervals 
precludes such analysis. Our baseline results are 
presented with these intervals for comparison. For the 
VLW approach we also tested assumptions regarding the 
reference value of a statistical life and how value of a 
statistical life is correlated with income, discussed in 
depth in the appendix, to account for uncertainty in value 
of a statistical life estimates.24 Finally, for each approach, 
economic losses are presented without PPP conversion to 
compare our estimates with results from similar studies.19
Role of the funding source
The funding source played no role in the acquisition or 
analysis of data, manuscript writing, or the decision to 
submit. All authors had full access to all data in the study 
and approved of its submission.
Results
128 countries with a combined population of 6·4 billion 
people (2013 population),23 or 90% of the global population, 
were assessed with the VLO approach (appendix). When 
aggregated by World Bank income classiﬁ cation, 75% of 
low-income countries’ populations and 90% of lower-
middle-income countries’ populations were assessed. 
More than 95% of the upper-middle-income and high-
income groups’ populations were assessed.
During 2015–30, and using Shrime and colleagues’ 
mean estimates (table 1),2 the surgical component of the 
diseases included in this study is estimated to result in a 
cumulative loss of $20·7 trillion, or 1·25% of projected 
economic output across the 128 countries included 
(ﬁ gure 1). This aggregate estimate is sensitive to 
uncertainty with respect to the burden of disease and the 
proportion of disease that is considered surgical, ranging 
from $12·1 trillion to $33·2 trillion (table 2). Annual 
losses as a share of total GDP are projected to rise, 
approximately doubling for all income groups between 
2015 and 2030 (ﬁ gure 2). They are also unevenly 
distributed by World Bank income classiﬁ cation and 
IHME region (ﬁ gure 2, ﬁ gure 3). 96% of GDP losses are 
projected to be secondary to injury and neoplasm, but the 
drivers of lost economic output vary signiﬁ cantly by 
region (ﬁ gure 3). Results by country and disease are 
given in the appendix.
175 countries with a population of 6·9 billion (2013), or 
97% of the global population, were assessed with the 
VLW approach (appendix). When aggregated by World 
Bank income classiﬁ cation, 90% of the population of 
low-income countries was evaluated, and more than 97% 
of the population of the remaining groups was included.
Economic welfare losses (VLW) do not represent actual 
losses in GDP, but they can be expressed relative to GDP 
to provide a sense of scale. Our baseline value of a 
statistical life assumptions suggest that the value of 
economic welfare losses in 2010 for the countries included 
in this study were equivalent to 17% of their 2010 GDP, or 
$14·5 trillion. When burden of disease uncertainty was 
accounted for, the estimates ranged from $8·7 trillion to 
$22·4 trillion. Welfare losses secondary to mortality, 
which are long-run estimates, make up $11·4 trillion of 
the estimated impact, while the short-run eﬀ ects of 
Figure 1: Annual and cumulative gross domestic product (GDP) losses secondary to surgical disease, value of 
lost output approach
Figure 2: Annual value of lost economic output due to surgical conditions expressed as percentage loss of 
GDP, value of lost output approach
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Digestive disorders 470 220 1010
Injury 7860 4330 13 240
Maternal disorders 80 20 220
Neonatal disorders 190 70 360
Neoplasm 12 120 7450 18 360
Total 20 720 12 090 33 190
Table 2: Total value of gross domestic product (GDP) losses secondary to surgical diseases, 2015–30, value 
of lost output approach
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morbidity incurred in 2010 contributed $3·1 trillion in 
losses (table 3). Our aggregate estimates are moderately 
sensitive to variations in the relation between value of a 
statistical life and income, and assuming otherwise 
baseline values range between $12·0 trillion and $16·9 
trillion (appendix). If the reference value of a statistical 
life is adjusted from the Environmental Protection 
Agency’s25 recommendation of $7·6 million (2006 US$) 
to the Organization for Economic Development 
and Cooperation’s recommendation of $3·0 million 
(2005 US$),26 the aggregate estimate falls to $8·2 trillion 
if all other assumptions are held constant. Injuries and 
neoplasm contribute to 95% of total economic losses. 
When stratiﬁ ed by income group, maternal, neonatal, 
and digestive disorders on average make up 26% and 14% 
of total losses in low-income and lower-middle income 
countries, respectively, compared with 4% in high-income 
countries (ﬁ gure 4). Results by country and disease are 
given in the appendix.
Discussion
This study demonstrates that surgical conditions impose a 
massive and previously unrecognised economic burden 
on a global scale (panel). The VLO approach, which 
accounts for market losses during 2015–30, suggests that 
surgical diseases will result in a cumulative loss of 1·25% 
of potential GDP, or $20·7 trillion, for the 128 countries 
we examined. These losses are expected to rise over time, 
and they will have the greatest impact on the most 
vulnerable populations because low-income and lower-
middle-income countries are projected to experience 
losses that are almost 50% greater than high-income 
countries (ﬁ gure 2). The inequitable distribution of the 
economic impact of surgical conditions is further 
magniﬁ ed when examined by region: central and southern 
sub-Saharan Africa are estimated to lose up to 2·5% of 
GDP in 2030—well more than double the losses that 
western Europe and north Africa and the Middle East will 
experience (ﬁ gure 3). Although injury is the main driver 
of these losses, maternal and neonatal disorders account 
on average for 10% of central sub-Saharan Africa’s 
foregone GDP; in comparison, maternal and neonatal 
disorders contribute to only 0·05% of western Europe’s 
projected economic losses, a more than 200-fold diﬀ erence 
(appendix). 
With the VLW approach, the death and disability 
incurred in 2010 for the 175 countries we examined are 
equivalent to roughly 17% of their aggregate 2010 GDP, or 
$14·5 trillion. As an equivalent share of GDP, high-
income countries are aﬀ ected most, with up to a 19% loss 
(ﬁ gure 4). These results, however, are driven largely by the 
crude, or non-age-adjusted, neoplasm-related mortality 
rates, which are currently more than twice as high in 
developed countries due in part to their older demographic 
proﬁ les.27 When neoplasm is excluded, we ﬁ nd a similar 
pattern as with the VLO approach, in which low-income 
countries bear the greatest share of the burden. We would 
re-emphasise here that the VLW and VLO estimates 
should not be compared because they are attempting to 
measure two conceptually distinct values: the VLW 
estimates include non-market welfare losses and in the 
context of mortality represent long-run losses and are 
therefore many times larger than the VLO estimates, 
which account only for market losses due to mortality (not 
morbidity) during the time period included in this study.
Not surprisingly given mortality rates, neoplasm and 
injury account for greater than 95% of the total economic 
Figure 4: Annual economic welfare losses secondary to surgical disease, expressed as equivalent percentage 
of gross domestic product (GDP), by World Bank income classiﬁ cation, value of lost welfare approach
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losses attributable to surgical disease in both approaches. 
However, maternal, digestive, and neonatal disorders 
make up a signiﬁ cantly greater proportion of losses in 
low-income and middle-income countries—up to 16% of 
VLO and 26% of VLW in low-income countries. These 
estimates reﬂ ect in part the lack of access to basic 
obstetric and surgical care in these countries, as well as 
the higher burden of non-communicable disease in high-
income countries. The stark contrasts in maternal and 
neonatal mortality rates between the developed and 
developing world, recently demonstrated by the Global 
Burden of Disease 2013 study,28,29 suggests that much of 
the burden we identiﬁ ed is avertable. Although one 
cannot estimate with certainty the potential economic 
gains to be realised with scaling up access to surgical 
services, the relative absence of maternal and neonatal 
burden in high-income countries suggests there could be 
substantial economic beneﬁ t to low-income and middle-
income countries in investing in surgical care. Finally, 
although neoplasm currently results in the greatest 
losses in the VLW approach for high-income countries, 
age-standardised rates of mortality are converging 
between the developed and developing world;27 as 
populations in low-income and middle-income countries 
age,30 these countries will face a similar if not greater 
economic impact than high-income countries currently, 
especially if surgical services are not available, since 
these remain the curative backbone of a large portion of 
cancer care.
These estimates, although concerning from the 
perspective of economic development, tell only part of 
the story. Bickler and colleagues17 assessed the impact of 
scaling up basic surgical services in low-income and 
middle-income countries and concluded that up to 
1·4 million deaths could be averted annually with access 
to surgery. From a purely humanitarian perspective, this 
degree of unnecessary mortality is indicative of striking 
inequality and the human toll of surgical conditions, 
falling most heavily on the poor and marginalised. 
However, policy makers necessarily require additional 
information to assist in decision making, and therefore 
economic impact estimates such as these can indicate 
the degree of urgency of diﬀ erent policy problems, and 
their broader impacts on development.11 We recognise 
that decisions about resource allocation cannot be made 
on the basis of economic burden studies alone, but our 
ﬁ ndings regarding the magnitude and inequitable 
distribution of the economic costs of surgical disease 
complement the existing global surgery literature on 
cost-eﬀ ectiveness31 and avertable burden.17 Ultimately, if 
one is concerned with saving lives and promoting 
economic growth, surgical conditions cannot be ignored.
Our results are not directly comparable to estimates 
produced by other studies because the assumptions 
applied across economic burden studies diﬀ er greatly. 
However, others have done studies with similar 
approaches and scope.19,32,33 Most recently, Bloom used the 
WHO EPIC model to assess non-communicable diseases 
(cardiovascular disease, neoplasm, chronic respiratory 
disease, mental illness, and diabetes), and estimated that 
they will result in $47 trillion (2010 USD) in lost output 
from 2011 to 2030.19 Notably, these estimates did not 
adjust for purchasing power parity. When our VLO results 
are expressed in US$ without PPP during 2011–30, we 
estimate $16·0 trillion in GDP losses, well in line with 
Bloom’s estimates given that the attributable burden of 
disease for the conditions we studied is less than in the 
non-communicable disease study, especially since we 
only account for the surgical proportion of each disease. 
Bloom also applied a model similar to our VLW approach 
to non-communicable diseases and found $22·8 trillion 
in economic welfare losses in 2010; without adjusting for 
PPP and using baseline value of a statistical life 
assumptions, the VLW for surgical conditions is 
$11·4 trillion. Although the assumptions of the non-
communicable disease study and our study diﬀ er, the 
similarity of the results is reassuring.
Our study is notable for several reasons. To our 
knowledge, it is the ﬁ rst to provide an estimate of the 
macroeconomic impact of surgical diseases at this scale 
through two distinct economic lenses. Our results 
suggest not only that surgical diseases will exact a large 
toll on the global economy, but that the costs are 
inequitably distributed with markedly greater impact on 
poor countries. The decision to include only countries 
with available data makes our aggregate estimates 
conservative.
 Panel: Research in context
Systematic review
Before initiating the study, we searched Medline and Google Scholar and failed to identify 
any studies that attempted to estimate the global macroeconomic burden of surgical 
disease. For this reason, a systematic review was not done. Previous eﬀ orts have been made 
to identify the global surgical burden of disease,1,2,17 but these studies were speciﬁ c to 
morbidity and mortality. As noted by Chisholm and colleagues11 in their review of economic 
burden methodology, there are countless studies that estimate the economic burden of 
diseases in the literature. We could identify no studies, however, that address surgical 
diseases at the global level. Although not speciﬁ c to surgery, others have attempted to 
identify the global macroeconomic burden of cancer and non-communicable diseases using 
similar methods and these are discussed further in the Discussion.19,21
Interpretation
When market losses secondary to surgical diseases are estimated during 2015–30, we 
estimate that up to 1·25% of GDP, or US$20·7 trillion, will be lost due to surgical disease. 
If welfare losses are incorporated, surgical diseases are estimated to result in 
$14·5 trillion dollars in 2010 alone. These losses are inequitably distributed, with 
low-income and middle-income countries facing greater relative costs than 
high-income countries. Although these ﬁ ndings cannot be used in isolation to inform 
decisions regarding resource allocation, there is a substantial and growing literature 
that supports the cost-eﬀ ectiveness of surgical interventions31 and makes clear that 
much of the current surgical burden of disease is avertable.17 Therefore, when the 
existing evidence is considered with our results, a strong case is made for elevating 
surgery as a global health priority.
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There are important limitations to the conclusions that 
can be drawn from economic impact studies, however, 
and our study is no exception. Although such studies can 
provide an assessment of the magnitude of a problem, 
they cannot be used in isolation for priority-setting, 
which requires information regarding the cost and 
eﬀ ectiveness of interventions.11 With that in mind, a 
robust literature base suggests that surgical interventions 
can be extremely cost-eﬀ ective in low-income and 
middle-income countries.31,34
There are also important technical limitations to this 
study. As with all models, our estimates are limited by data 
availability. Many of the data we used from low-income 
and middle-income countries are limited and the estimate 
of a model, as opposed to being measured directly. Data 
availability has also limited the ability to provide estimates 
in many countries, especially with the VLO approach, and 
high-income countries are necessarily over-represented 
given the relative degree of data availability. An important 
limitation with any economic model is that it cannot 
completely account for future technological advances, and 
the VLO approach in this study follows the EPIC model’s 
crude assumption of assigning a 1% rate of growth to 
productivity. We also recognise the signiﬁ cant role that 
uncertainty plays, especially with respect to supporting 
data and the inherent inexact, speculative nature of 
projection-based studies. When we incorporate the 
uncertainty intervals provided by IHME for their burden 
of disease estimates in addition to the CIs from Shrime’s 
survey data, the resulting intervals for both approaches are 
not insigniﬁ cant (VLO: $12·1–33·2 trillion, VLW: 
$8 ·7–22·4 trillion). These intervals in large part reﬂ ect the 
underlying uncertainty of IHME burden estimates, which 
incorporate a substantial amount of modelling in addition 
to primary data.
The VLW approach has several limitations. First, VSL 
estimates are derived from assessments of the monetary 
value that individuals place on small changes in mortality 
risk, and the linear assumption that is consequently made 
to determine the value of a statistical life is likely to be an 
oversimpliﬁ cation.35 There are further limitations to 
valuing morbidity,36 and the small number of formal 
studies on value of a statistical life in low-income and 
middle-income countries for either mortality or morbidity 
makes these estimates best-guesses. We account for the 
latter by applying a wide range of assumptions regarding 
how value of a statistical life varies with income.24 We 
would emphasise the eﬀ ect of baseline assumptions 
regarding the value of a statistical life; although varying 
the relation between income and value of a statistical life 
only moderately aﬀ ected our results, varying the reference 
value of a statistical life had a signiﬁ cant impact on our 
results, with our baseline estimate falling from $14 ·5 to 
$8·2 trillion. We also emphasise that our estimates can 
be compared directly to GDP in the case of the VLO 
approach, but only indirectly in the case of the VLW 
estimates, which incorporate non-market losses. Unlike 
the VLO estimates, the VLW estimates should not be 
interpreted as actual GDP lost. Finally, we have only 
considered ﬁ ve disease groups, and therefore our 
estimates may underestimate the total economic impact 
of surgical disease.
Our results suggest the macroeconomic impact of 
surgical disease is enormous and inequitably distributed, 
with poor countries often facing the largest burden. The 
notion that surgery is a necessary component of a fully 
functioning health-care system is rarely in dispute, and 
yet surgery’s place within the larger global health agenda 
is ill-deﬁ ned at best. When considered with the evidence 
of cost-eﬀ ectiveness of surgical interventions in 
low-income and middle-income countries,31 our results 
suggest that investing in surgery not only has the 
potential to save millions of lives, but could also 
contribute to improved overall economic welfare and 
developm ent.
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